A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999

Pediatric Blood and Cancer

Volumn 61, Issue 6, 2014, Pages 997-1002

  Castellanos, E Mauricio ^a   Barrantes, José Carlos ^b   Báez, L Fulgencio ^b   Gamboa, Yessica ^b   Peña, Armando ^b   Alabi, Soad ^b   Bonilla, Miguel ^b   Wang, Huaping ^c   Metzger, Monika L ^d   De Alarcón, Pedro A ^c  

^a Unidad Nacional de Oncología Pediátrica   (Guatemala)

^b Hospital de Niños Oncología Pediátrica ^*  (El Salvador)

^c UNIVERSITY OF ILLINOIS   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Chemotherapy; Hodgkin lymphoma; Radiation therapy

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GALLIUM; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MALE; MIXED CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL;

CHEMOTHERAPY; HODGKIN LYMPHOMA; RADIATION THERAPY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; NEOPLASM STAGING; PATIENT DROPOUTS; PREDNISONE; PROCARBAZINE; REMISSION INDUCTION; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 84901713471     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24905     Document Type: Article

References (16)

1. Howlander N, Noone AM, Krapcho M, et al. SEER cancer statistics review. http://seer.cancer.gov/ 2012; Ref Type: Electronic Citation.
2. Dinand V, Arya LS. Epidemiology of childhood Hodgkins disease: Is it different in developing countries? Indian Pediatr 2006; 43:141-147.
3. Diehl V, Thomas RK, Re D. Part II: Hodgkin's lymphoma-Diagnosis and treatment. Lancet Oncol 2004; 5:19-26.
4. Allemani C, Sant M, De Angelis R, et al. Hodgkin disease survival in Europe and the U.S.: Prognostic significance of morphologic groups. Cancer 2006; 107:352-360.
5. Hsu SC, Metzger ML, Hudson MM, et al. Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil. Pediatr Blood Cancer 2007; 49:139-144.
6. Faria SL, Vassallo J, Cosset JM, et al. Childhood Hodgkin's disease in Campinas, Brazil. Med Pediatr Oncol 1996; 26:90-94.
7. Jacobs P, King HS, Karabus C, et al. Hodgkin's disease in children. A ten-year experience in South Africa. Cancer 1984; 53:210-213.
8. Baez F, Ocampo E, Conter V, et al. Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol 1997; 8:247-250.
9. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31:1860-1861.
10. Arya LS, Dinand V, Thavaraj V, et al. Hodgkin's disease in Indian children: Outcome with chemotherapy alone. Pediatr Blood Cancer 2006; 46:26-34.
11. Sagar TG, Chandra A, Raman SG. Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: A progress report. Med Pediatr Oncol 2003; 40:66-69.
12. Tebbi CK, Mendenhall N, London WB, et al. Treatment of stage I, IIA, IIIA(1) pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: A Pediatric Oncology Group (POG) study. Pediatr Blood Cancer 2006; 46:198-202.
13. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: The results of P9425. Blood 2009; 114:2051-2059.
14. Buyukpamukcu M, Atahan L, Caglar M, et al. Hodgkin's disease in Turkish children: Clinical characteristics and treatment results of 210 patients. Pediatr Hematol Oncol 1999; 16:119-129.
15. Alebouyeh M, Moussavi F, Haddad-Deylami H, et al. Successful ambulatory treatment of Hodgkin's disease in Iranian children based on German-Austrian DAL-HD 85-90: Single institutional results. Ann Oncol 2005; 16:1936-1940.
16. Castellanos EM, Metzger ME, Baez LF, et al. A risk-adapted, response-based therapeutic regimen using a modified stanford V approach for the Treatment of children with high risk hodgkin lymphoma, AHOPCA LH 2004, a therapeutic regimen from the Central America and Dominican Republic Association of Pediatric Hematology Oncology. Blood 2009; 114:300. Ref Type: Abstract.